| Followers | 4 |
| Posts | 175 |
| Boards Moderated | 0 |
| Alias Born | 01/08/2022 |
Thursday, November 20, 2025 1:41:36 AM
Best to at least try an understand your enemy if possible. IMHO.
I also was trying to understand why SHORTS such as AF and MS are not illegally manipulating the stock when they have such a huge following (~ 30 million shorted) and they can just send out a single tweet to tank the stock (negative response) after a positive AVXL PR. I assumed it could be a type of collusion, but I guess not. Or I am not asking the question correctly. But it appears the Shorts are on solid ground in terms of free speech and opinions.
I asked the following question to Google AI.
"Pharma Bro, who has a large following, is a noted short of AVXL. On various occasions he has tweeted out a response to a positive AVXL PR and the stock immediately would tank after the tweet. Why isn't this market manipulation?"
-----Google AI Response (LAST ONE FOR ME)
A short seller's tweet is not automatically considered market manipulation because expressing an opinion about a stock, even with a large following, is protected as free speech, as long as it does not involve making
knowingly false or misleading statements of material fact. The key legal distinction lies in the veracity of the information and the intent to deceive investors.
Key Distinctions from Market Manipulation
Opinion vs. False Claims: Negative opinions or skepticism about a company's prospects are generally considered protected speech. In contrast, market manipulation, specifically "short-and-distort" schemes, involves spreading deliberate falsehoods or half-truths to trigger a price drop for profit. The burden is on regulators (like the SEC) or plaintiffs to prove the statements were verifiably false and intended to defraud.
Disclosure of Position: Reputable activist short sellers often disclose their short positions and the evidence supporting their negative view (e.g., reports, data analysis). This transparency is generally seen as legitimate market activity, as it adds information (or skepticism) to the market, even if it leads to volatility.
Intent: To prove manipulation, one must show the individual acted with the specific purpose of inducing others to buy or sell the security to create an artificial price, rather than simply stating a negative (but factually supported) view.
Case-by-Case Basis: The legality of such actions is assessed on a case-by-case basis. Regulators look for patterns of trading that indicate manipulative intent, such as publishing a report and then trading against the public recommendation almost immediately.
Why Martin Shkreli's Tweets Aren't (Necessarily) Illegal
In the specific case of Martin Shkreli and Anavex Life Sciences (AVXL), his tweets generally express a negative opinion or an analysis based on his own research or predictions (e.g., an anticipated negative opinion from the European Medicine Agency). While he has a large following, the statements themselves are often framed as his assessment, not verifiable, material falsehoods.
It is worth noting that Martin Shkreli was previously convicted of securities fraud for lying to investors about his hedge funds' performance and manipulating the stock of a different company, Retrophin, which involved actual theft and deception, not just a controversial tweet. His current trading and social media activities are under scrutiny, and he is barred by the SEC from associating with firms that sell securities or provide investment advice to the public.
Ultimately, the market reaction to his tweets, while significant, is a result of investors reacting to his opinion and reputation, not necessarily proof of an illegal "short-and-distort" scheme unless he is found to be disseminating known falsehoods and timing his trades to profit from the immediate, artificial price movement.
I also was trying to understand why SHORTS such as AF and MS are not illegally manipulating the stock when they have such a huge following (~ 30 million shorted) and they can just send out a single tweet to tank the stock (negative response) after a positive AVXL PR. I assumed it could be a type of collusion, but I guess not. Or I am not asking the question correctly. But it appears the Shorts are on solid ground in terms of free speech and opinions.
I asked the following question to Google AI.
"Pharma Bro, who has a large following, is a noted short of AVXL. On various occasions he has tweeted out a response to a positive AVXL PR and the stock immediately would tank after the tweet. Why isn't this market manipulation?"
-----Google AI Response (LAST ONE FOR ME)
A short seller's tweet is not automatically considered market manipulation because expressing an opinion about a stock, even with a large following, is protected as free speech, as long as it does not involve making
knowingly false or misleading statements of material fact. The key legal distinction lies in the veracity of the information and the intent to deceive investors.
Key Distinctions from Market Manipulation
Opinion vs. False Claims: Negative opinions or skepticism about a company's prospects are generally considered protected speech. In contrast, market manipulation, specifically "short-and-distort" schemes, involves spreading deliberate falsehoods or half-truths to trigger a price drop for profit. The burden is on regulators (like the SEC) or plaintiffs to prove the statements were verifiably false and intended to defraud.
Disclosure of Position: Reputable activist short sellers often disclose their short positions and the evidence supporting their negative view (e.g., reports, data analysis). This transparency is generally seen as legitimate market activity, as it adds information (or skepticism) to the market, even if it leads to volatility.
Intent: To prove manipulation, one must show the individual acted with the specific purpose of inducing others to buy or sell the security to create an artificial price, rather than simply stating a negative (but factually supported) view.
Case-by-Case Basis: The legality of such actions is assessed on a case-by-case basis. Regulators look for patterns of trading that indicate manipulative intent, such as publishing a report and then trading against the public recommendation almost immediately.
Why Martin Shkreli's Tweets Aren't (Necessarily) Illegal
In the specific case of Martin Shkreli and Anavex Life Sciences (AVXL), his tweets generally express a negative opinion or an analysis based on his own research or predictions (e.g., an anticipated negative opinion from the European Medicine Agency). While he has a large following, the statements themselves are often framed as his assessment, not verifiable, material falsehoods.
It is worth noting that Martin Shkreli was previously convicted of securities fraud for lying to investors about his hedge funds' performance and manipulating the stock of a different company, Retrophin, which involved actual theft and deception, not just a controversial tweet. His current trading and social media activities are under scrutiny, and he is barred by the SEC from associating with firms that sell securities or provide investment advice to the public.
Ultimately, the market reaction to his tweets, while significant, is a result of investors reacting to his opinion and reputation, not necessarily proof of an illegal "short-and-distort" scheme unless he is found to be disseminating known falsehoods and timing his trades to profit from the immediate, artificial price movement.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
